Qiagen expands into bloodstream infection syndromic testing

The company states: “QIAGEN (QGEN) announced its expansion into syndromic testing for bloodstream infections with the launch of the CE-IVDR-certified QIAstat-Dx BCID GPF Plus AMR Panel. The launch of this new QIAstat-Dx panel coincides with the ESCMID Global 2026 Congress in Munich (April 17-21), where QIAGEN will highlight its broad infectious disease portfolio, including QIAstat-Dx, the QuantiFERON-TB Gold Plus test for tuberculosis detection, alongside additional technologies supporting laboratory workflows, clinical decision-making and the development of Laboratory Developed Tests. The QIAstat-Dx BCID GPF Plus AMR Panel enables laboratories to identify 20 gram-positive bacterial and fungal pathogen targets and 10 antimicrobial resistance markers from positive blood cultures and pure colonies. This launch expands the QIAstat-Dx portfolio beyond respiratory, gastrointestinal and meningitis / encephalitis testing into bloodstream infection applications.”